Comparing biologicals for severe chronic rhinosinusitis with nasal polyps: A network meta‐analysis

Boechat, José Laerte; Silva, Diana; Sousa‐Pinto, Bernardo; Delgado, Luís

doi:10.1111/all.15205

Cited by 11 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Across comorbidities and baseline eosinophil markers, type 2 biologics resulted in more CRSwNP patients with reduced polyp size and nasal obstruction than placebo 14,15 . Consistent results concerning action onset, magnitude, and persistence of biologics effects have been observed regardless of treatment duration 9,15 . Rapid and sustained improvement has been observed after biologics treatment irrespective of prior surgery, comorbid asthma or AR, treatment duration (20–24 weeks vs. ≥40 weeks), baseline mean IgE levels, and baseline mean eosinophil counts.…”

mentioning

confidence: 68%

“…These NMAs favored dupilumab as the most effective and safest biologic for CRSwNP. [6][7][8][9] Clinical benefits of continuing biologic treatment were sustained from 24 weeks to the end of follow-up. 10 Besides positive results from randomized controlled trials (RCTs), IL-4Rαtargeted therapy was more effective than anti-IL-5, anti-IL-5Rα, and anti-IgE biologics in a real-life retrospective analysis of patients with aspirin-exacerbated respiratory disease.…”

Section: E D I T O R I a L Knowledge Gaps In Using Type 2 Biologics F...mentioning

confidence: 99%

“…Thus, indirect comparisons between biologics targeting type 2 inflammation have been performed via network meta‐analysis (NMA). These NMAs favored dupilumab as the most effective and safest biologic for CRSwNP 6–9 . Clinical benefits of continuing biologic treatment were sustained from 24 weeks to the end of follow‐up 10 .…”

mentioning

confidence: 98%

See 2 more Smart Citations

Knowledge gaps in using type 2 biologics for real‐world treatment of chronic rhinosinusitis with nasal polyps

Lou

Zhang

2022

Allergy

View full text Add to dashboard Cite

mentioning

confidence: 68%

Section: E D I T O R I a L Knowledge Gaps In Using Type 2 Biologics F...mentioning

confidence: 99%

See 1 more Smart Citation

Knowledge gaps in using type 2 biologics for real‐world treatment of chronic rhinosinusitis with nasal polyps

Lou

Zhang

2022

Allergy

View full text Add to dashboard Cite

“…Nowadays, anti-IgE treatment has been approved in many countries as add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with intranasal corticosteroids does not provide adequate disease control. Noticeably, although Omalizumab is useful in the treatment of CRSwNP, a recent network meta-analysis and systematic review showed that anti-IgE antibodies are less effective than anti-IL-4 receptor antibodies ( 113 , 114 )…”

Section: The Function Of Ige and Anti-ige Treatment In Npsmentioning

confidence: 99%

Local Immunoglobulin E in nasal polyps: Role and modulation

Shen

Zhang²,

Yang³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

In the airway, IgE is traditionally regarded as a key mediator in allergic diseases, such as AR and allergic asthma. However, growing evidence demonstrates the importance of local IgE in airway inflammatory diseases, irrespective of the presence of allergy. In this review, we discuss the most recent evidence for IgE in chronic rhinosinusitis with nasal polyps(CRSwNP), including the local IgE’s characteristics, the modulation of its synthesis, and its function. The levels of local IgE are significantly elevated in polyps independently of IgE serum levels and atopic status. Local IgE, which is correlated with type 2 inflammation, is polyclonal and functional. IgE is produced by active B cells and is dependent on the class switch recombination(CSR). In NPs, this process is triggered by not only allergens but also microbial colonization, especially the superantigen- Staphylococcus aureus. The production of local IgE is modulated by lymphocytes(such as Tfh, ILC2s, iTreg), cytokines(such as IL-4, IL-13, IFN-γ, TGF-β, IL-2, IL-21), transcription factors, and B cell-intrinsic factor. Due to the central role of IgE in NPs, it is regarded as an ideal target for therapy and has been proved to be clinically successful. Based on this knowledge, we believe that exploring the trigger and regulatory factors for the activation of local B cells and CSR to IgE will provide more valuable information for us to recognize the pathological mechanisms of local IgE and offer the possible option for new therapeutic targets of nasal polyps.

show abstract

“…Nowadays, anti-IgE treatment has been approved in many countries as add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with intranasal corticosteroids does not provide adequate disease control. Noticeably, although Omalizumab is useful in the treatment of CRSwNP, a recent network metaanalysis and systematic review showed that anti-IgE antibodies are less effective than anti-IL-4 receptor antibodies (113,114)…”

Section: Anti-ige Treatment In Npsmentioning

confidence: 99%

Local Immunoglobulin E in nasal polyps: Role and modulation

Shen

Zhang

Bachert

2022

Preprint

View full text Add to dashboard Cite

In the airway, IgE is traditionally regarded as a key mediator in allergic diseases, such as AR and allergic asthma. However, growing evidence demonstrates the importance of local IgE in airway inflammatory diseases, irrespective of the presence of allergy. In this review, we discuss the most recent evidence for IgE in chronic rhinosinusitis with nasal polyps(CRSwNP), including the local IgE’s characteristics, the modulation of its synthesis, and function. The levels of local IgE are significantly elevated in polyps independently of IgE serum levels and atopic status. Local IgE is polyclonal and functional, which is correlated with type 2 inflammation. IgE is produced by active B cells and is dependent on the classing switch recombination(CSR). In NPs, this process is triggered by not only allergens but also microbial colonization, especially the superantigen- Staphylococcus aureus. The production of local IgE is modulated by lymphocytes(such as Tfh, ILC2s, iTreg), cytokines(such as IL-4, IL-13, IFN-γ, TGF-β, IL-2, IL-21), transcription factors, and B cell intrinsic factor. Due to the central role of IgE in NPs, it is regarded as an ideal target for therapy and has been proved to be clinically successful. Based on this knowledge, we believe that exploring the trigger and regulatory factors for the activation of local B cells and CSR to IgE will provide more valuable information for us to recognize the pathological mechanisms of local IgE and offer the possible option for new [therapeutic](#/javascript:;) targets of NPs.

show abstract

Comparing biologicals for severe chronic rhinosinusitis with nasal polyps: A network meta‐analysis

Cited by 11 publications

References 9 publications

Knowledge gaps in using type 2 biologics for real‐world treatment of chronic rhinosinusitis with nasal polyps

Knowledge gaps in using type 2 biologics for real‐world treatment of chronic rhinosinusitis with nasal polyps

Local Immunoglobulin E in nasal polyps: Role and modulation

Local Immunoglobulin E in nasal polyps: Role and modulation

Contact Info

Product

Resources

About